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New insights into the effects of the protein moiety of oxidized namely the excessive generation of hypochlorous acid
LDL (oxLDL). Oxidative stress has been implicated in the (HOCl), can transform the lipoprotein into a high-uptake
cardiovascular complications in chronic renal failure patients. form for macrophages without significant lipid (per) oxi-Lipoprotein oxidation is involved in the genesis of atheroscle-
dation. Apo B100 is the main target for this oxidant [2].rosis. Both the lipid and the protein moieties of low-density
A recent study indicated that HOCl also alters the physi-lipoproteins (LDL) are subject to oxidation. We have shown
that oxidation of LDL by hypochlorous acid (HOCl) in vitro, ologic properties of high-density lipoproteins (HDL) by
reflecting increased myeloperoxidase (MPO) activity in vivo, generating a proatherogenic lipoprotein particle, partic-
leads mainly to modifications of apolipoproteins, such that ularly modified on the protein moiety [3]. The enzymethe latter in turn induce high rates of apoptosis in a human
myeloperoxidase (MPO) catalyzes the production ofmonocytic cell line via a caspase-dependent pathway. These
HOCl from hydrogen peroxide (H2O2) and chloride inin vitro oxidative changes of LDL protein moiety, if shown to
occur to a significant extent in uremic patients in vivo, may activated neutrophils and monocytes, which are present
represent an important pathway in the pathogenesis of athero- under inflammatory conditions. The importance of MPO
genesis.
as a potential in vivo oxidant is underlined by the pres-
ence of enzymatically-active MPO in human atheroscle-
OXIDATION OF LOW-DENSITY LIPOPROTEINS rotic lesions [4]. Moreover, it has been demonstrated
(LDL) ON PROTEIN MOIETY: A NOVEL that MPO is able to bind to LDL, enhancing site-directed
PATHWAY IN ATHEROGENESIS? oxidation of the lipoprotein [5]. Most importantly, spe-
cific HOCl-dependent oxidation markers were identifiedLipoprotein oxidation is involved in the genesis of
in the development of atherosclerotic lesions, stronglyatherosclerosis. Several methods have been developed
supporting the involvement of the MPO-H2O2-chlorideto promote LDL oxidation in vitro. However, it proved
system. Both mass spectrometry analysis [6] and immu-to be difficult to identify the mechanisms that are physio-
nohistochemical studies [7, 8] demonstrated that HOCl-logically relevant in vivo. Both the lipid and the protein
generated protein oxidation products are present inmoieties of LDL are subject to oxidation, and both can be
human atherosclerotic lesions. The pathophysiologic rel-oxidized in vivo [1]. Oxidation of the LDL-lipid moiety is
evance of protein oxidation products, such as plasmacommonly thought to represent the initial step of oxida-
advanced oxidation protein products (AOPP), has al-tive LDL modification. Nevertheless, in vitro, this oxida-
ready been documented in the context of coronary arterytive pathway requires the presence of high concentra-
disease in nonuremic subjects [9].tions of free metal ions (e.g., copper or iron), and due
to multiple redundant mechanisms for chelating redox-
active free metal ions in vivo, the role of free transition PROTEIN OXIDATION PRODUCTS
metal ions has been questioned. Moreover, Heinecke’s AND UREMIA
group cannot find evidence of metal-induced lipoprotein
Oxidative stress has been implicated in the cardiovas-damage at early stages of human atherosclerotic plaque
cular complications that affect chronic renal failure (CRF)formation [1]. Although lipid peroxidation could also
patients [10]. We have previously shown that uremiclead to oxidative modification of apolipoprotein B100
patients, in addition to having several lipoprotein distur-(apo B100), the core protein of LDL, another pathway,
bances, present protein oxidation products, such as AOPP
or carbonyls [11, 12]. An increase in plasma 3-chlorotyro-
Key words: HOCl-oxLDL, apoptosis, atherogenesis. sine level, another specific HOCl oxidation protein prod-
uct, has been also demonstrated in chronic hemodialysis 2003 by the International Society of Nephrology
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patients [13]. The demonstration of markedly elevated
concentrations of HOCl-modified protein in the plasma
of CRF patients [12–15], and the presence of oxidatively
modified lipoproteins in kidney vascular structures [16]
would indicate enhanced MPO activity in blood and vari-
ous tissues of uremic patients, including the arterial wall.
In keeping with this, it has been shown that basal plasma
MPO activity levels of patients on regular hemodialysis
treatment were higher than those of healthy controls
[17]. Of note, we recently found that plasma AOPP was
associated with common carotid artery intima-media
thickness (CCA-IMT), a process probably exacerbated
by intravenous iron administration in patients undergo-
ing epoetin therapy [18]. This observation supports the
role of protein oxidation products in the early atheroscle-
rosis of dialysis patients.
DIVERSE BIOLOGICAL EFFECTS OF Fig. 1. Effects of caspase inhibitor Z-VAD.fmk (50 mol/L) on
HOCl-oxLDL-induced apoptosis. Apoptotic cells were analyzed usingHOCl-oxLDL
flow cytometry with propidium iodide staining.
Growing evidence shows that HOCl-oxLDL exert bio-
logical functions distinct of those known for copper-
oxLDL. Zabe et al [19] showed that HOCl-oxLDL has
the potential for altering platelet function, with proper- engulfed without inducing an inflammatory response.
ties different from those of the copper-oxidized counter- However, this dogma was recently challenged by studies
parts. Likewise, Woenckhaus et al [20] demonstrated that showing Fas-mediated activation of several pro-inflam-
oxLDL generated by metal ion catalysis predominantly matory genes during the apoptotic process [25]. In addi-
release monocyte chemotactic factors, such as MCP-1 tion, with regard to atherosclerotic plaques, recent in
(monocyte chemotactic protein-1), whereas HOCl-oxLDL vitro studies have suggested that the removal of apo-
induce the secretion and synthesis of the chemokine in- ptotic cells may be inefficient in such a complex tissue
terleukin 8 in human monocytes. Moreover, we showed [26]. Moreover, apoptosis, through its procoagulant and
in our laboratory that HOCl-oxLDL were more potent proadhesive potentials, may play a critical role in both
than copper-oxLDL in inducing macrophage respiratory plaque and blood thrombogenicity, and may be an impor-
burst and retained this activating potential even after tant step in the transition from stable to unstable athero-
delipidation. This observation is in support of a crucial sclerotic disease [27]. In keeping with this, an increased
role of the protein moiety of oxLDL in the macrophage- number of MPO-expressing macrophages is detected in
mediated oxidative injury involved in atherogenesis [21]. eroded or ruptured plaques, causing acute coronary syn-
Atherosclerosis can be considered as a chronic in- dromes, but not in human fatty streaks, supporting a possi-
flammatory disease associated with enhanced apoptotic ble role of protein oxidation products in atheroma compli-
cell death in vascular cells, including smooth muscle cells cations, in particular, acute coronary syndromes [28].
[22], endothelial cells [23], and monocyte-macrophages
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incubation with copper sulfate. In a recent study [24],
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